Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis.
about
Multiple possible inaccuracies cast doubt on a recent report suggesting selective serotonin reuptake inhibitors to be toxic and ineffective.Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants' Efficacy and Harm.ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors.
P2860
Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Bias in the reporting of harms ...... and anxiety: A meta-analysis.
@en
Bias in the reporting of harms ...... and anxiety: A meta-analysis.
@nl
type
label
Bias in the reporting of harms ...... and anxiety: A meta-analysis.
@en
Bias in the reporting of harms ...... and anxiety: A meta-analysis.
@nl
prefLabel
Bias in the reporting of harms ...... and anxiety: A meta-analysis.
@en
Bias in the reporting of harms ...... and anxiety: A meta-analysis.
@nl
P50
P1476
Bias in the reporting of harms ...... and anxiety: A meta-analysis.
@en
P2093
Erick H Turner
Peter de Jonge
P304
P356
10.1016/J.EURONEURO.2016.09.370
P407
P577
2016-09-19T00:00:00Z